治疗神经脊髓炎谱系病的新进展：文献综述。

IF 2.6 3区医学 Q2 ANESTHESIOLOGY

Clinical Journal of Pain Pub Date : 2023-05-16 eCollection Date: 2023-01-01 DOI:10.3389/fopht.2023.1130971

Padmaja Sudhakar, Khawla Abusamra, Mangayarkarasi Thandampallayam, Ashwini Kini

{"title":"治疗神经脊髓炎谱系病的新进展：文献综述。","authors":"Padmaja Sudhakar, Khawla Abusamra, Mangayarkarasi Thandampallayam, Ashwini Kini","doi":"10.3389/fopht.2023.1130971","DOIUrl":null,"url":null,"abstract":"Neuromyelitis Optica spectrum disorder (NMOSD) is a relapsing autoimmune disease of the central nervous system (CNS) where aquaporin-4 water channels are the antigenic target of the disease. The spectrum of the disease involves regions of the CNS where the water channel is widely expressed including the spinal cord, the optic nerve, dorsal medulla, brainstem, and thalamus/hypothalamus. Management of NMOSD includes acute as well as long term treatment. Acute symptoms are typically treated with intravenous corticosteroids and/or plasma exchange while long-term treatment involves the use of immunosuppression/immune modulation. The year 2019 is thought to be the \"year of the NMOSD\" as three new medications became available for this devastating disease. In this review, FDA approved NMOSD medications are discussed.","PeriodicalId":50678,"journal":{"name":"Clinical Journal of Pain","volume":"32 1","pages":"1130971"},"PeriodicalIF":2.6000,"publicationDate":"2023-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182166/pdf/","citationCount":"0","resultStr":"{\"title\":\"New advancements in the management of Neuromyelitis Optica spectrum disease: literature review.\",\"authors\":\"Padmaja Sudhakar, Khawla Abusamra, Mangayarkarasi Thandampallayam, Ashwini Kini\",\"doi\":\"10.3389/fopht.2023.1130971\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Neuromyelitis Optica spectrum disorder (NMOSD) is a relapsing autoimmune disease of the central nervous system (CNS) where aquaporin-4 water channels are the antigenic target of the disease. The spectrum of the disease involves regions of the CNS where the water channel is widely expressed including the spinal cord, the optic nerve, dorsal medulla, brainstem, and thalamus/hypothalamus. Management of NMOSD includes acute as well as long term treatment. Acute symptoms are typically treated with intravenous corticosteroids and/or plasma exchange while long-term treatment involves the use of immunosuppression/immune modulation. The year 2019 is thought to be the \\\"year of the NMOSD\\\" as three new medications became available for this devastating disease. In this review, FDA approved NMOSD medications are discussed.\",\"PeriodicalId\":50678,\"journal\":{\"name\":\"Clinical Journal of Pain\",\"volume\":\"32 1\",\"pages\":\"1130971\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2023-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182166/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Journal of Pain\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/fopht.2023.1130971\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ANESTHESIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Journal of Pain","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fopht.2023.1130971","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

神经脊髓炎视网膜谱系障碍（NMOSD）是中枢神经系统（CNS）的一种复发性自身免疫性疾病，水通道蛋白-4是该病的抗原靶点。该病的病变范围涉及水通道广泛表达的中枢神经系统区域，包括脊髓、视神经、背髓、脑干和丘脑/下丘脑。NMOSD 的治疗包括急性和长期治疗。急性症状通常采用静脉注射皮质类固醇和/或血浆置换治疗，而长期治疗则包括使用免疫抑制/免疫调节。2019 年被认为是 "NMOSD 年"，因为有三种新药可用于治疗这种毁灭性疾病。本综述将讨论 FDA 批准的 NMOSD 药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

New advancements in the management of Neuromyelitis Optica spectrum disease: literature review.

Neuromyelitis Optica spectrum disorder (NMOSD) is a relapsing autoimmune disease of the central nervous system (CNS) where aquaporin-4 water channels are the antigenic target of the disease. The spectrum of the disease involves regions of the CNS where the water channel is widely expressed including the spinal cord, the optic nerve, dorsal medulla, brainstem, and thalamus/hypothalamus. Management of NMOSD includes acute as well as long term treatment. Acute symptoms are typically treated with intravenous corticosteroids and/or plasma exchange while long-term treatment involves the use of immunosuppression/immune modulation. The year 2019 is thought to be the "year of the NMOSD" as three new medications became available for this devastating disease. In this review, FDA approved NMOSD medications are discussed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Journal of Pain 医学-临床神经学

CiteScore

5.40

自引率

3.40%

发文量

118

审稿时长

4-8 weeks

期刊介绍： The Clinical Journal of Pain explores all aspects of pain and its effective treatment, bringing readers the insights of leading anesthesiologists, surgeons, internists, neurologists, orthopedists, psychiatrists and psychologists, clinical pharmacologists, and rehabilitation medicine specialists. This peer-reviewed journal presents timely and thought-provoking articles on clinical dilemmas in pain management; valuable diagnostic procedures; promising new pharmacological, surgical, and other therapeutic modalities; psychosocial dimensions of pain; and ethical issues of concern to all medical professionals. The journal also publishes Special Topic issues on subjects of particular relevance to the practice of pain medicine.